| Literature DB >> 30072128 |
Ryo Yanagisawa1, Makoto Tanaka1, Fumiaki Yashima1, Takahide Arai1, Takashi Kohno1, Hideyuki Shimizu2, Keiichi Fukuda1, Toru Naganuma3, Kazuki Mizutani4, Motoharu Araki5, Norio Tada6, Futoshi Yamanaka7, Shinichi Shirai8, Minoru Tabata9, Hiroshi Ueno10, Kensuke Takagi11, Akihiro Higashimori12, Yusuke Watanabe13, Masanori Yamamoto14, Kentaro Hayashida15.
Abstract
Cognitive impairment is common in patients underwent transcatheter aortic valve implantation (TAVI) and might affect procedure outcomes. This study evaluated the incidence of preprocedural cognitive impairment and its impact on clinical outcomes after TAVI. We analyzed the data of 1,111 patients (age ≥70 years) obtained from the Optimized CathEter vAlvular iNtervention (OCEAN-TAVI) registry. The cognitive performance of all patients was assessed using the Mini-Mental State Examination (MMSE) at baseline. We evaluated the 1-year cumulative mortality after TAVI according to the MMSE performance. Cognitive impairment was present in 420 (38%) of 1,111 patients. Compared with patients with normal cognition, those with cognitive impairment showed higher cumulative all-cause and noncardiovascular mortality rates at 1 year (14% vs. 8%, p = 0.001; 11% vs. 5%, p <0.001, respectively). Moreover, cognitive impairment increased the risk of mortality from sepsis (2% vs. 0.4%; hazard ratio, 4.2; 95% confidence interval, 1.3 to 13.5; p = 0.02). In adjusted models, cognitive impairment was an independent risk factor for 1-year all-cause mortality (adjusted hazard ratio, 2.1; 95% confidence interval, 1.1 to 4.0; p = 0.02). Although patients with cognitive impairment had more in-hospital adverse outcomes, including prolonged hospital stays, major bleeding and vascular complications, and acute kidney injury, than did those with normal cognition, the 30-day mortality was similar between the groups (1% in the two groups; p >0.99). In conclusion, cognitive impairment based on the MMSE score was an independent predictor of mortality at 1 year after TAVI.Entities:
Mesh:
Year: 2018 PMID: 30072128 DOI: 10.1016/j.amjcard.2018.05.026
Source DB: PubMed Journal: Am J Cardiol ISSN: 0002-9149 Impact factor: 2.778